Abstract
Prostate cancer is the most common malignancy among men found to be the second leading cause of male cancer-related mortality due to development of resistance against androgen deprivation therapy (ADT). With the advancement in understanding of prostate cancer, numbers of agents have been emerged to target Androgen-Receptor (AR) signaling for the treatment of castration resistant prostate cancer (CRPC). Food and Drug Administration (FDA) has recently approved enzalutamide (XTANDI) for the treatment of CRPC. Androgen receptor promotes the prostate cancer progression after transformation. Androgen receptor signaling leads to CRPC when cellular nucleus binds to DNA and increases pro cancer gene expression. In phase ΙΙΙ clinical trial, enzalutamide showed that 160 mg once daily oral administration is well tolerated and significantly enhanced overall survival in men with CRPC after chemotherapy, demonstrated by reduction in the serum prostate specific antigen (PSA) level and increased survival rate by 4.8 months.
Keywords: Enzalutamide, Anti-androgen, Androgen deprivation therapy (ADT), Castration resistant prostate cancer (CRPC).
Mini-Reviews in Medicinal Chemistry
Title:Enzalutamide: A Novel Anti-androgen with Prolonged Survival Rate in CRPC Patients
Volume: 13 Issue: 10
Author(s): Richa Dhingra, Tina Sharma, Sukhminder Singh, Shivani Sharma, Prince Tomar, Manav Malhotra and T.R. Bhardwaj
Affiliation:
Keywords: Enzalutamide, Anti-androgen, Androgen deprivation therapy (ADT), Castration resistant prostate cancer (CRPC).
Abstract: Prostate cancer is the most common malignancy among men found to be the second leading cause of male cancer-related mortality due to development of resistance against androgen deprivation therapy (ADT). With the advancement in understanding of prostate cancer, numbers of agents have been emerged to target Androgen-Receptor (AR) signaling for the treatment of castration resistant prostate cancer (CRPC). Food and Drug Administration (FDA) has recently approved enzalutamide (XTANDI) for the treatment of CRPC. Androgen receptor promotes the prostate cancer progression after transformation. Androgen receptor signaling leads to CRPC when cellular nucleus binds to DNA and increases pro cancer gene expression. In phase ΙΙΙ clinical trial, enzalutamide showed that 160 mg once daily oral administration is well tolerated and significantly enhanced overall survival in men with CRPC after chemotherapy, demonstrated by reduction in the serum prostate specific antigen (PSA) level and increased survival rate by 4.8 months.
Export Options
About this article
Cite this article as:
Dhingra Richa, Sharma Tina, Singh Sukhminder, Sharma Shivani, Tomar Prince, Malhotra Manav and Bhardwaj T.R., Enzalutamide: A Novel Anti-androgen with Prolonged Survival Rate in CRPC Patients, Mini-Reviews in Medicinal Chemistry 2013; 13 (10) . https://dx.doi.org/10.2174/13895575113139990003
DOI https://dx.doi.org/10.2174/13895575113139990003 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases
Current Protein & Peptide Science Calcium Carbonate Microparticles as Carriers of <sup>224</sup>Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Current Radiopharmaceuticals Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets The Adiponectin Signaling Pathway as a Novel Pharmacological Target
Mini-Reviews in Medicinal Chemistry Recent Advances of Chitosan and its Derivatives in Biomedical Applications
Current Medicinal Chemistry MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design A Discussion of MicroRNAs in Cancers
Current Bioinformatics Data Integration in Functional Analysis of MicroRNAs
Current Bioinformatics The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly
Current Neuropharmacology Natural Product Gossypol and its Derivatives in Precision Cancer Medicine
Current Medicinal Chemistry DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Neurological Aspects of Grief
CNS & Neurological Disorders - Drug Targets Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review
Current Drug Discovery Technologies Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Current Status and Perspectives in Peptide Receptor Radiation Therapy
Current Pharmaceutical Design Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Expeditious Entry to Functionalized Pseudo-peptidic Organoselenide Redox Modulators via Sequential Ugi/SN Methodology
Anti-Cancer Agents in Medicinal Chemistry Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup>Lu and Conjugated to Peptides
Current Radiopharmaceuticals A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry